Submit Manuscript  

Article Details


Selective Histone Deacetylase Inhibitors with Anticancer Activity

[ Vol. 16 , Issue. 4 ]

Author(s):

Nan Ma, Ying Luo, Ying Wang, Chenzhong Liao, Wen-Cai Ye and Sheng Jiang   Pages 415 - 426 ( 12 )

Abstract:


HDAC inhibitors (HDACIs), which can be used to kill cancer cells through inhibiting histone deacetylase activity or altering the structure of chromatin, have emerged as efficacious agents in the treatment of cancer. With SAHA, FK228, belinostat and panobinostat approved by the FDA, displaying satisfying activity in both haematological and solid tumors of various tissues, efforts to create selective HDACIs have been attracted attention over the past several years. Herein, we mainly review the progress of selective HDAC inhibitors including class-selective and isoform-selective HDAC inhibitors.

Keywords:

Class I, Class II, Class III, HDAC, HDAC1, HDAC6, Selective histone deacetylase inhibitors.

Affiliation:

Institute of Traditional Chinese Medicine & Natural Products, College of Pharmacy, Jinan University, Guangzhou 510632, P.R. China., Laboratory of Medicinal Chemistry, Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou 510530, P.R. China.

Graphical Abstract:



Read Full-Text article